Bennett Nikki E, Johnson Elizabeth A, Gray Peter B
Am J Vet Res. 2024 Dec 20;86(2). doi: 10.2460/ajvr.24.09.0265. Print 2025 Feb 1.
Direct-to-consumer (D2C) genetic tests are increasingly accessible to pet owners, with commercial genetic companies entering veterinary distribution markets. This study evaluated veterinary care providers' (VCPs) awareness of the D2C genetic industry, experiences with clients' inquiries, perceptions of clinical utility, and confidence in interpreting test results.
Veterinary care providers attending a professional conference (February 19 through 23, 2023) were invited to complete an online survey.
229 VCPs began the survey, and 218 completed all sections. Respondents were predominately veterinarians (131 of 218 [60.3%]), mostly working in small animal practices (160 of 218 [73.7%]), with dogs (206 of 218 [94.9%]) and cats (199 of 218 [91.7%]). 186 of 229 participants (81.2%) encountered clients using or intending to use D2C genetic tests, often seeking recommendations or the VCP's opinion about genetic services. 86 of 131 veterinarians (65.6%) and 36 of 44 registered veterinary technicians (81.8%) perceived genetic testing as clinically useful. Veterinarians reported higher confidence in interpreting dog than cat results, with additional differences related to breed versus health information.
This study indicates that VCPs are generally aware of D2C genetic testing, with licensed veterinarians and veterinary technicians recognizing its clinical utility. However, veterinarian confidence levels with assisting clients in understanding their results varies by species and test type.
As trends in D2C genetic testing persist, there is a need for interventions to address the lack of guidelines and improve VCP attitudes and confidence in assisting clients with these tests. This will involve genetic companies offering targeted support and continuing education to address gaps in confidence related to dog, cat, breed, and health information.
宠物主人越来越容易获得直接面向消费者(D2C)的基因检测服务,商业基因公司已进入兽医分销市场。本研究评估了兽医护理提供者(VCP)对D2C基因产业的认知、处理客户咨询的经验、对临床效用的看法以及解读检测结果的信心。
邀请参加专业会议(2023年2月19日至23日)的兽医护理提供者完成一项在线调查。
229名VCP开始参与调查,218名完成了所有部分。受访者主要是兽医(218名中的131名[60.3%]),大多从事小动物诊疗工作(218名中的160名[73.7%]),涉及犬类(218名中的206名[94.9%])和猫类(218名中的199名[91.7%])。229名参与者中的186名(81.2%)遇到过使用或打算使用D2C基因检测的客户,这些客户经常寻求建议或VCP对基因服务的看法。131名兽医中的86名(65.6%)和44名注册兽医技术人员中的36名(81.8%)认为基因检测具有临床实用性。兽医报告称,解读犬类检测结果的信心高于猫类,此外在品种与健康信息方面也存在差异。
本研究表明,VCP普遍知晓D2C基因检测,有执照的兽医和兽医技术人员认可其临床效用。然而,兽医在协助客户理解检测结果方面的信心水平因物种和检测类型而异。
随着D2C基因检测趋势的持续,需要采取干预措施来解决缺乏指导方针的问题,并改善VCP在协助客户进行这些检测方面的态度和信心。这将涉及基因公司提供有针对性的支持和继续教育,以弥补在犬类、猫类、品种和健康信息方面信心的差距。